<![CDATA[Introduction: Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disorder complicating severe asthma and cystic fibrosis. Systemic corticosteroids, the mainstay of treatment, carry substantial cumulative toxicity, and the steroid-sparing role of the anti-immunoglobulin E (IgE) antibody omalizumab remained incompletely defined, particularly in South-East Asia where ABPA is under-recognised. We aimed to synthesise the most recent evidence on omalizumab in reducing exacerbations and oral corticosteroid (OCS) burden in adults with ABPA. Methods: Following the PRISMA 2020 statement, six databases were searched for original studies enrolling at least ten ABPA patients treated with omalizumab. Standardised mean differences (Hedges' g) were pooled using a DerSimonian-Laird random-effects model with the Hartung-Knapp-Sidik-Jonkman correction. Risk of bias, subgroup, sensitivity and meta-regression analyses, and the GRADE certainty of evidence were assessed. Results: Ten studies (n = 286) were qualitatively synthesised; eight (n = 241) entered the quantitative pool. Omalizumab produced a moderate-to-large favourable composite effect (Hedges' g = -0.69; 95% CI -1.12 to -0.25; p = 0.007). Outcome-specific pooling confirmed reduced exacerbations (g = -0.74), reduced OCS dose (g = -0.81), and improved FEV1 (g = +0.48) and asthma control (g = +0.69), corresponding to approximately 1.9 fewer exacerbations per year and 9 mg/day prednisolone equivalent. Heterogeneity was substantial (I-squared = 78.4%) but the effect was robust across leave-one-out and sensitivity analyses. Conclusion: Omalizumab confers a clinically meaningful steroid-sparing benefit in adults with ABPA, supporting its adoption as maintenance therapy, pending adequately powered randomised trials in South-East Asian populations.]]>
Copyrights © 2026
